Arrowhead Stock Insiders


USD 31.20  1.57  5.30%   

Arrowhead Pharma employes about 329 people. The company is managed by 17 executives with total tenure of roughly 155 years, averaging almost 9.0 years of service per executive having 19.35 employees per reported executive. Discussion of Arrowhead Pharma management performance can provide insight into the enterprise performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Arrowhead Pharma future performance.
Please continue to Trending Equities.
  Christopher Anzalone  CEO
CEO and President Director, CEO of Calando, CEO of Tego, CEO of Nantope, CEO of Leonardo and CEO of Ablaris Therapeutics
  Douglas Given  Chairman
Chairman of the Board
  Edward Frykman  Chairman
Director, Chairman of Audit Committee, Member of Nomination Committee, Member of Compensation Committee, Director of Insert Therapeutics Inc, Director of Unidym, Director of Aonex and Director of Calando

Arrowhead Pharma Management Team Effectiveness

Arrowhead Pharma has return on total asset (ROA) of (13.41) % which means that it has lost $13.41 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (33.79) %, meaning that it created substantial loss on money invested by shareholders. Arrowhead Pharma management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.

Arrowhead Pharma Workforce Comparison

Arrowhead Pharma is number one stock in number of employees category among related companies. The total workforce of Biotechnology industry is presently estimated at about 3,329. Arrowhead Pharma holds roughly 329 in number of employees claiming about 10% of stocks in Biotechnology industry.

Arrowhead Pharma Profit Margins

The company has Profit Margin (PM) of (61.58) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (59.73) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.6.

Arrowhead Pharma Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Arrowhead Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Arrowhead Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Arrowhead Pharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Arrowhead Pharma Benchmark Summation

The output start index for this execution was zero with a total number of output elements of sixty-one. Arrowhead Pharma Price Series Division is a division of Arrowhead Pharma price series and its benchmark/peer.

Arrowhead Pharma Notable Stakeholders

An Arrowhead Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Arrowhead Pharma often face trade-offs trying to please all of them. Arrowhead Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Arrowhead Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Christopher Anzalone - CEO and President Director, CEO of Calando, CEO of Tego, CEO of Nantope, CEO of Leonardo and CEO of Ablaris TherapeuticsProfile
Douglas Given - Chairman of the BoardProfile
Edward Frykman - Director, Chairman of Audit Committee, Member of Nomination Committee, Member of Compensation Committee, Director of Insert Therapeutics Inc, Director of Unidym, Director of Aonex and Director of CalandoProfile
Susan Boynton - Vice President - Regulatory AffairsProfile
Zhen Li - Senior Vice President - Chemistry & ManufacturingProfile
Peter Leone - Vice President-Strategy & Program ManagementProfile
Kenneth Myszkowski - CFOProfile
Bruce Given - COOProfile
Charles McKenney - Independent DirectorProfile
Michael Perry - Independent DirectorProfile
Douglass Given - DirectorProfile
Mauro Ferrari - Scientific Advisor, Director, Member of Nomination Committee and Member of Compensation CommitteeProfile
William Waddill - Independent DirectorProfile
Vince Anzalone - IR Contact OfficerProfile
Chad Rubin - IR Contact OfficerProfile
Patrick OBrien - General CounselProfile
David Lewis - Chief Scientific OfficerProfile

About Arrowhead Pharma Management Performance

The success or failure of an entity such as Arrowhead Pharma often depends on how effective the management is. Arrowhead Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Arrowhead management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Arrowhead management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California. Arrowhead Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 329 people.
The data published in Arrowhead Pharma's official financial statements usually reflect Arrowhead Pharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Arrowhead Pharma. For example, before you start analyzing numbers published by Arrowhead accountants, it's critical to develop an understanding of what Arrowhead Pharma's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Arrowhead Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Arrowhead Pharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Arrowhead Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Arrowhead Pharma. Please utilize our Beneish M Score to check the likelihood of Arrowhead Pharma's management to manipulate its earnings.

Arrowhead Pharma Workforce Analysis

Traditionally, organizations such as Arrowhead Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Arrowhead Pharma within its industry.

Arrowhead Pharma Manpower Efficiency

Return on Arrowhead Pharma Manpower

Revenue Per Employee759.7 K
Revenue Per Executive14.7 M
Net Loss Per Employee467.9 K
Net Loss Per Executive9.1 M
Working Capital Per Employee197.1 K
Working Capital Per Executive3.8 M
Please continue to Trending Equities. You can also try Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Complementary Tools for analysis

When running Arrowhead Pharma price analysis, check to measure Arrowhead Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharma is operating at the current time. Most of Arrowhead Pharma's value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Arrowhead Pharma's price. Additionally, you may evaluate how the addition of Arrowhead Pharma to your portfolios can decrease your overall portfolio volatility.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Transaction History
View history of all your transactions and understand their impact on performance
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Is Arrowhead Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arrowhead Pharma. If investors know Arrowhead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arrowhead Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Arrowhead Pharma is measured differently than its book value, which is the value of Arrowhead that is recorded on the company's balance sheet. Investors also form their own opinion of Arrowhead Pharma's value that differs from its market value or its book value, called intrinsic value, which is Arrowhead Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arrowhead Pharma's market value can be influenced by many factors that don't directly affect Arrowhead Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arrowhead Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Arrowhead Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arrowhead Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.